<DOC>
	<DOCNO>NCT02009293</DOCNO>
	<brief_summary>In study evaluate effect Pirfenidone cough quality life patient idiopathic pulmonary fibrosis ( IPF ) treat Pirfenidone daily practice . The hypothesis Pirfenidone decrease cough increase quality life .</brief_summary>
	<brief_title>The Effect Pirfenidone Cough Patients With Idiopathic Pulmonary Fibrosis</brief_title>
	<detailed_description>Rationale : Idiopathic Pulmonary Fibrosis ( IPF ) progressive fibrotic lung disease unknown cause median survival 3-5 year . No curative treatment exists , though 2011 Pirfenidone approve treatment IPF appear slow decline lung function . In patient IPF , common symptom cough breathlessness . Cough major distress disable symptom also independent predictor disease progression death IPF . Recent preliminary data suggest possible effect Pirfenidone cough . Objective : In study want objectively measure effect Pirfenidone cough patient IPF treat Pirfenidone daily practice . Study design : This prospective , observational , international multicenter study . Intervention : Objective 24-hour cough frequency record use Leicester Cough Monitor ( LCM ) , validate ambulatory cough monitoring system , prior start Pirfenidone treatment . The cough recording repeat 4 week 12 week treatment Pirfenidone . At day cough record , patient ask fill questionnaire relate cough quality life . Patient treat accord normal clinical practice Physician 's discretion . Main study parameters/endpoints : The primary endpoint change cough frequency measure Leicester cough monitor week 12 compare baseline . Secondary endpoint look relationship cough , change cough , quality life clinical parameter .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Pirfenidone</mesh_term>
	<criteria>Diagnosis IPF accord American Thoracic Society ( ATS ) / European Respiratory Society ( ERS ) criterion ( 5 ) , definite probable patient eligible Written inform consent Daily cough relate IPF ( exclusion cause ) present &gt; 8 week cough score visual analogue scale ≥ 40 mm . Carbon monoxide transfer capacity correct hemoglobin ( TLCOc ) ≥ 30 % Forced Vital Capacity ( FVC ) ≥ 50 % Pirfenidone therapy initiate history positive Gastro Esophageal Reflux ( GER ) , use proton pump inhibitor ( PPI ) &gt; 4 week Opiates , antitussive medication , antihistamine , steroid &gt; equivalent 10 mg prednisone Nacetylcysteine ( NAC ) within two week study Change steroid &lt; 10 mg , inhalation steroid within 2 week study History bronchial hyper responsiveness asthma relevant airway obstruction ( FEV1/FVC &lt; 0.7 ) within 6 week start sign respiratory tract infection , change sputum production fever .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>idiopathic pulmonary fibrosis</keyword>
	<keyword>cough</keyword>
	<keyword>quality life</keyword>
</DOC>